Conference Details - Overview
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
7th Annual The Best of San Antonio: Breast Cancer—Bench to Bedside
Sheraton Chicago Hotel & Towers
Chicago, IL
February 6, 2010
Conference Overview
CME-Certified Symposium
This activity is presented by Physicians’ Education Resource in conjunction with Loyola University.
The 7th Annual The Best of San Antonio: Breast Cancer—Bench to Bedside symposium will highlight the latest advances in the fight against breast cancer unveiled at the 2009 San Antonio Breast Cancer Symposium. This program will feature a diverse panel of internationally recognized breast cancer experts who will provide a candid and critical review of the clinically important abstracts. Dr. Kathy Albain, the Program Director, together with the outstanding faculty will highlight the more promising advances in treatment for early-stage and advanced/metastatic breast cancer, including hormonal, cytotoxic, and biologic approaches as well as prognostic and predictive assays. Translational science, including molecular and receptor biology, and pathology research that impact ongoing and future studies will also be discussed. In addition, advances in surgery, radiation therapy, and risk reduction will be presented.
This dynamic half-day symposium is designed to meet the educational objectives of all breast cancer specialties and is intended to guide participants from the laboratory to the general health care setting—from “Bench to Bedside.” The goal of this program is to have each participant leave with a new awareness of the innovative strategies available across the wide spectrum of breast cancer research, treatment, and prevention and to apply these strategies directly to the practice setting.
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.At the conclusion of this symposium, you should be able to:
- Assess the latest clinical developments in the diagnosis of breast cancer
- Evaluate genomic and proteomic tools for the estimation of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making
- Review adjuvant endocrine options for postmenopausal patients, including timing and sequencing of aromatase inhibitors in adjuvant regimens and the integration of bone-targeted agents
- Examine the efficacy and safety of chemotherapy and targeted therapies, in early-stage breast cancer
- Assess data on the optimization of surgery and radiation therapy for the treatment of early-stage breast cancer
- Review standard and novel therapeutic options for patients with HER2-overexpressing metastatic breast cancer, including combinatorial therapies and options beyond progression on standard therapy
- Examine the efficacy and safety of novel classes of targeted biologic agents, including angiogenesis inhibitors, currently under investigation for the treatment of metastatic breast cancer
- Assess available and investigational agents for improving bone health or preventing recurrence in patients receiving adjuvant therapy for breast cancer or for treating skeletal metastases
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- Genomic Health
- sanofi-aventis U.S.
- AstraZeneca
- Novartis Oncology